Sofia Fund Company Profile

Background

Overview

Sofia Fund is a venture capital firm based in St. Paul, Minnesota, specializing in investing in and growing exceptional women-led companies. Established in 1998, the firm has invested over $10 million in more than 50 companies, focusing on gender-diverse teams with scalable business models that leverage technology to address real-world problems.

Mission and Vision

The mission of Sofia Fund is to empower women entrepreneurs by providing them with the necessary resources, expertise, and capital to build successful businesses. The firm envisions a future where women-led companies achieve parity in funding and realize their full economic potential. Research indicates that women-led businesses generate 20% more revenue with 50% less investment compared to other companies, highlighting the significant opportunity in supporting these ventures.

Primary Area of Focus

Sofia Fund concentrates on sectors such as information technology, enterprise solutions, health and wellness, and clean technology. The firm seeks investments in companies with proprietary positions, scalable business models focusing on B2B markets, and well-defined, demonstrable business models with proof-of-concept revenues.

Industry Significance

As one of the longest-running angel investment groups focused exclusively on funding women-owned and women-led startups, Sofia Fund plays a pivotal role in addressing the funding disparity faced by women entrepreneurs. By actively managing and supporting its portfolio companies, the firm contributes to the growth and success of women-led businesses, thereby fostering diversity and innovation within the entrepreneurial ecosystem.

Key Strategic Focus

Core Objectives

• Empowerment of Women Entrepreneurs: Provide capital and resources to women-led businesses to enhance their growth and success.

• Achieve Parity in Funding: Address the funding gap by increasing the proportion of venture capital allocated to women-led companies.

• Maximize Investor Returns: Identify and invest in high-growth opportunities that offer substantial returns for investors.

Specific Areas of Specialization

• Information Technology: Investing in companies that employ software, hardware, apps, analytics, IoT, and AI technologies to deliver transformative outcomes.

• Enterprise Solutions: Supporting businesses that enhance operational efficiency and business processes through innovative solutions.

• Health and Wellness: Focusing on technology applications in the health and wellness sector to improve outcomes and accessibility.

Key Technologies Utilized

Sofia Fund emphasizes investments in technologies such as software, hardware, applications, analytics, Internet of Things (IoT), and artificial intelligence (AI) that provide value to businesses and consumers.

Primary Markets or Conditions Targeted

The firm targets B2B markets with large, growing, and well-defined opportunities, focusing on companies that have a proprietary position and a scalable business model. Investments are typically in the form of preferred stock in C corporations, with the expectation of exits within 3-5 years.

Financials and Funding

Funding History

Sofia Fund has raised over $10 million across multiple funds since its inception in 1998. The firm operates its second fund, a $5.5 million fund, which has invested in several companies to date.

Recent Funding Rounds

Specific details regarding recent funding rounds are not publicly disclosed. However, the firm continues to actively invest in women-led companies, with a focus on sectors such as information technology, enterprise solutions, health and wellness, and clean technology.

Notable Investors

Sofia Fund's investors include individual angel investors who are committed to supporting women entrepreneurs and fostering diversity in the entrepreneurial ecosystem. The firm operates as a cross between individual angel investors and venture capitalists, providing both capital and strategic support to its portfolio companies.

Intended Utilization of Capital

The capital raised is utilized to invest in high-growth, women-led companies, providing them with the necessary resources to scale their operations, develop products, and expand into new markets. The firm emphasizes active management and support, leveraging its expertise and networks to help portfolio companies achieve successful exits.

Pipeline Development

Key Pipeline Candidates

Sofia Fund's portfolio includes several notable women-led companies:

• CogRx: Developing small molecule therapeutics targeting toxic proteins associated with Alzheimer's disease.

• Dispatch Goods: Revolutionizing circular packaging to reduce single-use plastics.

• Joylux: Creating innovative wellness solutions for women's intimate health.

• Landit: Providing a technology platform to enhance the success and engagement of women in the workplace.

• Oculogica: Developing technology to transform traumatic brain injury diagnosis.

• Strategikon Pharma: Offering a new approach to planning, budgeting, and sourcing clinical trials.

• TiLT: Providing a platform to redefine the employee leave experience.

Stages of Clinical Trials or Product Development

Specific details regarding the stages of clinical trials or product development for each portfolio company are not publicly disclosed. However, the firm focuses on companies with well-defined, demonstrable business models and proof-of-concept revenues, indicating that these companies are in advanced stages of development.

Target Conditions

The portfolio companies address various conditions and needs, including:

• Alzheimer's Disease: Targeting toxic proteins associated with cognitive decline.

• Environmental Sustainability: Reducing single-use plastics through innovative packaging solutions.

• Women's Health: Improving intimate health and wellness for women.

• Workplace Diversity: Enhancing the success and engagement of women in professional environments.

• Traumatic Brain Injury: Transforming diagnosis and treatment approaches.

• Clinical Trials: Innovating the planning and execution of clinical trials.

• Employee Benefits: Redefining the employee leave experience to improve retention and satisfaction.

Relevant Timelines for Anticipated Milestones

Specific timelines for anticipated milestones for each portfolio company are not publicly disclosed. However, Sofia Fund typically seeks investments with exits within 3-5 years, indicating a focus on companies with clear growth trajectories and potential for profitable outcomes within this timeframe.

Technological Platform and Innovation

Proprietary Technologies

Sofia Fund's portfolio companies utilize various proprietary technologies, including:

• Small Molecule Therapeutics: Developing drugs targeting specific proteins associated with diseases.

• Circular Packaging Solutions: Innovating packaging to reduce environmental impact.

• Wellness Devices: Creating home-use devices for women's health.

• Workplace Platforms: Providing technology to enhance workplace diversity and engagement.

• Diagnostic Tools: Developing non-invasive devices for brain injury detection.

• Clinical Trial Management: Offering platforms to streamline clinical trial processes.

• Employee Leave Management: Providing solutions to improve employee leave experiences.

Significant Scientific Methods

The portfolio companies employ various scientific methods, including:

• Biological Research: Targeting specific proteins for therapeutic interventions.

• Sustainable Design: Innovating packaging to be environmentally friendly.

• Medical Device Development: Creating devices for health monitoring and treatment.

• Data Analytics: Utilizing data to enhance workplace diversity and engagement.

• Neuro-Diagnostics: Employing eye-tracking technology for brain injury assessment.

• Clinical Trial Optimization: Streamlining trial planning and execution.

• HR Technology: Developing platforms to manage employee leave processes.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed, the portfolio companies operate in sectors where AI and data analytics can play a significant role, such as in health diagnostics, workplace engagement platforms, and clinical trial management.

Leadership Team

Key Executive Profiles

• Cathy Connett, CEO: Cathy is the CEO and managing partner of Sofia Fund. She is also the president and founder of CorConnections, specializing in guiding businesses through new initiatives, equity infusions, ownership transitions, and building alliances. Cathy has served as the director of the Center for Entrepreneurship at the University of Minnesota Duluth and has a strong track record in investment management and entrepreneurial leadership.

• Bill Connett, Partner: Bill has extensive experience in strategy development, business growth, and operational execution, serving as a partner and advisor to multiple companies.

• Erin Hanson, Partner: Erin brings expertise in venture capital and supporting women entrepreneurs, contributing to the firm's investment evaluation and portfolio management.

• Kelly Connett, Partner: Kelly contributes skills in business development and fostering relationships between investors and startups.

Together, the leadership team's combined experience in venture capital, entrepreneurship, and business advisory underpins Sofia Fund's mission to empower women-led companies and deliver strong investor returns.